Using the industry peer median EV/Revenue multiple (trailing + forward), Accuray Incorporated (ARAY) has a fair value of $14.40 based on 10 comparable companies in the Medical - Devices industry.
USD in millions except Fair Price. Subject company highlighted.
| Mkt Cap ($M) | Trailing EV/Revenue | Forward EV/Revenue | |
|---|---|---|---|
| Accuray IncorporatedARAY | 39 | 0.3x | 0.4x |
| Anteris Technologies Global Corp. | 242 | 121.2x | 29.1x |
| Profound Medical Corp. | 217 | 8.6x | 4.6x |
| Anika Therapeutics, Inc. | 197 | 1.4x | 1.1x |
| TriSalus Life Sciences, Inc. | 169 | 4.1x | 3.1x |
| Milestone Pharmaceuticals Inc. | 165 | 97.2x | 4.5x |
| Rapid Micro Biosystems, Inc. | 117 | 3.6x | 3.6x |
| Owlet, Inc. | 104 | 0.8x | 0.8x |
| MaxCyte, Inc. | 90 | 2.7x | 2.5x |
| LENSAR, Inc. | 68 | 1.0x | 1.3x |
| Rani Therapeutics Holdings, Inc. | 61 | 28.5x | 10.3x |
| Industry Median | 3.8x | 3.3x | |
| (*) Revenue | 459 | 434 | |
| = Enterprise Value | 1,756 | 1,442 | |
| (-) Net Debt | 119 | 119 | |
| Equity Value | 1,637 | 1,323 | |
| (/) Outstanding shares | 103 | 103 | |
| Fair Price | $16 | $13 | |
Disclaimer: Sweet Value Lab provides estimated intrinsic values for informational purposes only. This is not financial advice. All models rely on assumptions that may not reflect future performance. Always do your own research before making investment decisions.